SCHEMBL6441432

SCHEMBL6441432

Cc1cc(Br)cc(N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1181671 0.81
SCHEMBL249664 0.81
Bromide SCHEMBL680431 0.78 POLB (0.39)
SCHEMBL28302673 0.75
SCHEMBL16506708 0.74
SCHEMBL29659053 0.74
SCHEMBL14681831 0.74 NPC1 (0.36)
SCHEMBL2541709 0.74
SCHEMBL10399561 0.74
SCHEMBL31324837 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4200297-B1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2026-05-13 EP disclosed
EP-4308096-B1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 US disclosed
US-12486267-B2 Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-02 US disclosed
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) 2025-09-04 US disclosed
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof GENENTECH, INC. (US) 2025-06-24 US disclosed
WO-2025123007-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-06-12 WO disclosed
WO-2025111582-A1 AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D GENENTECH, INC. (US) 2025-05-30 WO disclosed
WO-2025076523-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS, INC. (US) 2025-04-10 WO disclosed
WO-2025072395-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-03 WO disclosed
WO-2020035052-A1 PYRAZINE COMPOUNDS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-02-20 WO disclosed
EP-3609888-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Metacrine, Inc. (US) 2020-02-19 EP disclosed
CN-110637011-A Farnesoin X receptor agonists and uses thereof 梅塔科林公司 2019-12-31 CN disclosed
CN-110637015-A Farnesoin X receptor agonists and uses thereof 梅塔科林公司 2019-12-31 CN disclosed
WO-2018170182-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF METACRINE, INC. (US) 2018-09-20 WO disclosed
EP-1448547-B1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2005-04-20 EP disclosed
US-6831087-B2 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics HOFFMANN-LA ROCHE INC. 2004-12-14 US disclosed
EP-1448547-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-25 EP disclosed
US-20030119870-A1 Pyridine substituted isoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-06-26 US disclosed
WO-2003040128-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-15 WO disclosed